Company / EPS (Diluted)
REGENXBIO Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$4.59
FY2025
5-year range
-$6.50 / $2.91
FY2021-FY2025
Trend
+29.4%
vs FY2024
Sector context
#170 of 204
Health Care
What the data says
REGENXBIO Inc.'s eps (diluted) of $-4.59 is lower than 83% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-6.50 in FY2024 to $2.91 in FY2023.
Based on SEC 10-K filings.
-4.59 in FY2025.
Declined from $2.91 to $-4.59 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 204This company -$4.59 Sector average -$0.98
▼
-368.6% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 29.4% year-over-year.
- Ranks #170 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.59 | +29.4% |
| FY2024 | -$6.50 | -323.4% |
| FY2023 | $2.91 | +197.7% |
| FY2022 | -$2.98 | -15.5% |
| FY2021 | -$2.58 | -194.5% |
| FY2020 | $2.73 | +211.4% |
| FY2019 | -$2.45 | -2.9% |
| FY2018 | -$2.38 | +8.1% |
| FY2017 | -$2.59 | -42.3% |
| FY2016 | -$1.82 | +27.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026